Please assess the completion status of the following clinical trial:

Trial Title: Phase 1 Trial of Na-ASP-2 Hookworm Vaccine in Previously Infected Brazilian Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females between 18 and 45 years, inclusive.~* Known residents of the Municipality of Novo Oriente de Minas, Minas Gerais, Brazil.~* Good general health as determined by means of the screening procedure.~* Completed a 3-dose albendazole treatment for documented hookworm infection during the previous 3 months.~* Available for the duration of the trial (42 weeks).~* Willingness to participate in the study as evidenced by signing the informed consent document.~Exclusion Criteria:~* Pregnancy as determined by a positive urine β-hCG (if female).~* Participant unwilling to use reliable contraception methods up until one month following the third immunization (if female).~* Currently lactating and breast-feeding (if female).~* Inability to correctly answer all questions on the informed consent comprehension questionnaire.~* Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, or renal disease by history, physical examination, and/or laboratory studies.~* Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study protocol.~* Laboratory evidence of liver disease (alanine aminotransferase \[ALT\] greater than 64 U/l \[females\] or greater than 58 U/l \[males\]).~* Laboratory evidence of renal disease (serum creatinine greater than 1.1 mg/dl \[females\] or greater than 1.3 mg/dl \[males\], or more than trace protein or blood on urine dipstick testing).~* Laboratory evidence of hematologic disease (absolute leukocyte count \<3000/mm3 or \>12.5 x 103/mm3; hemoglobin \<10.3 g/dl \[females\] or \<11.0 g/dl \[males\]; absolute lymphocyte count \<900/mm3; or platelet count \<120,000/mm3).~* Other condition that in the opinion of the investigator would jeopardize the safety or rights of a volunteer participating in the trial or would render the subject unable to comply with the protocol.~* Participation in another investigational vaccine or drug trial within 30 days of starting this study.~* Volunteer has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.~* History of a severe allergic reaction or anaphylaxis.~* Severe asthma as defined by the need for regular use of inhalers or emergency clinic visit or hospitalization within the last 6 months.~* Positive ELISA for HCV.~* Positive ELISA for HBsAg.~* Known immunodeficiency syndrome.~* Use of corticosteroids (excluding topical or nasal) or immunosuppressive drugs within 30 days of starting this study.~* Receipt of a live vaccine within past 4 weeks or a killed vaccine within past 2 weeks prior to entry into the study.~* History of a surgical splenectomy.~* Receipt of blood products within the past 6 months.~* Previous receipt of a primary series of any hepatitis B vaccine.~* History of allergy to yeast.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 10 mcg Na-ASP-2/Alhydrogel (Type: EXPERIMENTAL): Na-ASP-2 Hookworm Vaccine
- Butang hepatitis B vaccine (Type: ACTIVE_COMPARATOR): Hepatitis B Vaccine - comparator vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues